UNCY
Income statement / Annual
Last year (2023), Unicycive Therapeutics, Inc.'s total revenue was $675,000.00,
a decrease of 29.02% from the previous year.
In 2023, Unicycive Therapeutics, Inc.'s net income was -$30.54 M.
See Unicycive Therapeutics, Inc.�s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$675,000.00
|
$951,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$0.00 |
$7,000.00 |
$1,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$675,000.00 |
$944,000.00 |
-$1,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
1 |
0.99 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$12.90 M
|
$12.44 M
|
$6.08 M
|
$1.02 M
|
$795,000.00
|
$344,000.00
|
| General & Administrative
Expenses |
$8.55 M
|
$6.57 M
|
$2.90 M
|
$1.01 M
|
$1.17 M
|
$608,000.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$8.55 M
|
$6.57 M
|
$2.90 M
|
$1.01 M
|
$1.17 M
|
$608,000.00
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$21.45 M |
$19.00 M |
$8.98 M |
$2.02 M |
$1.96 M |
$952,000.00 |
| Cost And Expenses |
$21.45 M |
$19.00 M |
$8.98 M |
$2.02 M |
$1.96 M |
$952,000.00 |
| Interest Income |
$615,000.00 |
$6,000.00 |
$628,000.00 |
$244,000.00 |
$139,000.00 |
$168,000.00 |
| Interest Expense |
$82,000.00 |
$6,000.00 |
$628,000.00 |
$244,000.00 |
$139,000.00 |
$0.00 |
| Depreciation &
Amortization |
$284,000.00
|
$7,000.00
|
$1,000.00
|
$2.02 M
|
$1.96 M
|
$952,000.00
|
| EBITDA |
-$30.18 M
|
-$18.05 M
|
-$8.98 M
|
$0.00
|
-$63,000.00
|
$0.00
|
| EBITDA Ratio |
-44.71 |
-18.98 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-30.78
|
-18.98
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$9.77 M
|
-$6,000.00
|
-$1.04 M
|
-$244,000.00
|
-$202,000.00
|
-$168,000.00
|
| Income Before Tax |
-$30.54 M |
-$18.06 M |
-$10.02 M |
-$2.26 M |
-$2.17 M |
-$1.12 M |
| Income Before Tax Ratio
|
-45.25
|
-18.99
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$6,000.00 |
$615,000.00 |
$244,000.00 |
$139,000.00 |
-$952,000.00 |
| Net Income |
-$30.54 M |
-$18.06 M |
-$10.63 M |
-$2.51 M |
-$2.30 M |
-$1.12 M |
| Net Income Ratio |
-45.25 |
-18.99 |
0 |
0 |
0 |
0 |
| EPS |
-1.28 |
-1.2 |
-0.71 |
-0.16 |
-0.27 |
-0.14 |
| EPS Diluted |
-1.28 |
-1.2 |
-0.71 |
-0.16 |
-0.27 |
-0.14 |
| Weighted Average Shares
Out |
$24.54 M
|
$15.06 M
|
$15.00 M
|
$15.25 M
|
$8.43 M
|
$7.94 M
|
| Weighted Average Shares
Out Diluted |
$24.54 M
|
$15.06 M
|
$15.00 M
|
$15.25 M
|
$8.47 M
|
$7.94 M
|
| Link |
|
|
|
|
|
|
